

END



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REVOCATION OF ALL PREVIOUS POWERS OF ATTORNEY AND

NEW POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The undersigned Queen's University at Kingston, whose full post office address is Kingston, Ontario K7L 3N6, Canada, hereby revokes all previous powers of attorney for the application for a patent entitled **Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype**, Serial No. **10/042,039**, which was filed on October 25, 2001, and hereby appoints Stephen J. Scribner (Registration No. 44,452) and Carol Miernicki Steeg (Registration No. 39,539) of PARTEQ Innovations, Queen's University, Kingston, Ontario, K7L 3N6, Canada, telephone no. (613) 533-2342, as its attorneys or agents to prosecute this application, to receive the patent and all correspondence relating to this application, and to transact all business in the United States Patent and Trademark Office connected therewith, with full power of substitution and revocation, and ratifies any act done by the said attorneys or agents in respect of the application.


Please address all correspondence and telephone calls to:

Stephen J. Scribner
PARTEQ Innovations
Room 1625, Biosciences Complex
Queen's University
Kingston, ON K7L 3N6
CANADA
(613) 533-2342

Date: 19 Oct 2005

QUEEN'S UNIVERSITY AT KINGSTON

Name: Patrick Deane
Title: Vice-Principal (Academic)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Queen's University at KingstonApplication No./Patent No.: 10/042,039 Filed/Issue Date: October 25, 2001Entitled: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell PhenotypeQueen's University at Kingston, a university,
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Charles H. Graham and Lynne-Marie Postovit To: Queen's University at Kingston
The document was recorded in the United States Patent and Trademark Office at
Reel 012943, Frame 0563, or for which a copy thereof is attached.

2. From: Michael A. Adams and Jeremy P.W. Heaton To: IMAJH Corporation
The document was recorded in the United States Patent and Trademark Office at
Reel 012942, Frame 0273, or for which a copy thereof is attached.

3. From: IMAJH Corporation To: Queen's University at Kingston
The document was recorded in the United States Patent and Trademark Office at
Reel 012943, Frame 0578, or for which a copy thereof is attached.

☒ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

19 Oct 2005
Date

Patrick Deane
Typed or printed name

[Signature]
Signature

Vice-Principal (Academic)
Title

STATEMENT UNDER 37 CFR 3.73(b)

Supplemental Sheet

Continuation of chain of title for Application No. 10/042,039 filed October 25, 2001

4. From Queen's University at Kingston to Cellegy Pharmaceuticals Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 014506, Frame 0111.
5. From Cellegy Pharmaceuticals, Inc. to Queen's University at Kingston
for which a copy thereof is attached.



NOTARIAL CERTIFICATE

I certify that I have compared the attached copy with the original Assignment

dated 7 October 2005

from Cellegy Pharmaceuticals, Inc.

to Queen's University at Kingston

and that the said copy is a true copy of the original.

Dated at Kingston, Ontario this 19 day of October, 2005.

Stephen J. Scribner
Notary Public
Province of Ontario

**Stephen Joseph Scribner, Notary Public,
Province of Ontario, limited to the attestation
of instruments and the taking of affidavits, for
PARTEQ Research and Development Innovations.
Expires January 9, 2007.**

ASSIGNMENT

WHEREAS **Cellegy Pharmaceuticals, Inc.** (herein after referred to as ASSIGNOR), a corporation organized under the laws of the State of Delaware, whose full post office address is 1000 Marina Boulevard, Suite 300, Brisbane, California, 94005, U.S.A., is the beneficial owner of the entire right, title, and interest in and to patents, patent applications, and provisional patent applications listed in the Appendix annexed hereto, and to any patent applications claiming priority to any of the patents, patent applications, and provisional patent applications (hereinafter referred to collectively as the "Patents") with the full right to convey the interest assigned by this Assignment; and

WHEREAS, **Queen's University at Kingston** (hereinafter referred to as ASSIGNEE), a non-profit educational corporation incorporated by Royal Charter, whose full post office address is Kingston, Ontario, K7L 3N6, Canada, is desirous of acquiring from ASSIGNOR the entire right, title, and interest in and to the Patents;

NOW THEREFORE, in consideration and in exchange for the sum of one dollar (\$1.00), and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby sells, assigns, transfers, and sets over to ASSIGNEE its entire worldwide right, title, and interest, including priority rights under the International Convention for the Protection of Industrial Property, in and to the Patents and to any patent applications claiming priority to any of the Patents, together with the entire right, title, and interest in and to all continuations in whole or in part, divisions, renewals, extensions, prolongations, reissues, and re-examinations of any of the Patents, including all common law rights therein, with the right to sue for and collect damages, including past infringement, the same to be held and enjoyed by ASSIGNEE for its use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives, as the same would have been held and enjoyed by ASSIGNOR if the assignment and sale had not been made;

AND ASSIGNOR hereby agrees to cooperate with ASSIGNEE in the prosecution of the Patents, and to execute such further lawful documents, assurances, applications, and other instruments as may be required to give effective legal and registered title to ASSIGNEE in and to the Patents, together with the entire right, title, and interest in and to all continuations in whole or in part, divisions, renewals, extensions, prolongations, re-issues, and re-examinations of any of the Patents; all without further consideration, but at the sole expense of ASSIGNEE;

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents or the Comptroller (as the case may be) to issue any and all Letters Patent resulting from the Patents in the annexed Appendix to ASSIGNEE.

EXECUTED at San Francisco, California, U.S.A., the 7TH day of October, 2005


PHARMACEUTICALS *JJC*
CELLEGY PHARMACEUTICALS, INC.

By:

John J. Chandler
Name: JOHN J. CHANDLER
Title: VP CORPORATE DEVELOPMENT

NOTARIAL CERTIFICATE

On this 7th day of October, 2005, before me, the undersigned Notary Public in and for the State of California, U.S.A., personally came JOHN J. CHANDLER, whom I know to be the person who signed the attached Assignment document on behalf of Cellegy Pharmaceuticals, Inc. I acknowledge the above to be his signature, and that he signed and delivered the above instrument as his voluntary act and deed for the purposes herein set forth.



Thom O'Brien

Name:
Notary Public
State of California

APPENDIX

1. U.S. Provisional Patent Application Serial No. 60/199,757, filed April 26, 2000
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
2. U.S. Patent Application Serial No. 60/277,469, filed March 21, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
3. International Patent Application Serial No. PCT/CA01/00566, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
4. U.S. Patent No. 6,946,484, issued September 20, 2005
U.S. Patent Application Serial No. 09/842,547, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
5. U.S. Patent Application Serial No. 10/042,039, filed October 25, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
6. Australian Patent Application Serial No. 2001250221, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
7. Canadian Patent Application Serial No. 2,407,466, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit

8. Japanese Patent Application Serial No. 2001-577987, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
9. Israeli Patent Application Serial No. 152428, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
10. European Patent No. 1 278 547, issued November 3, 2004
European Patent Application Serial No. 01 923 448.3, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
11. Mexican Patent No. 229903
Mexican Patent Application Serial No. PA/a/2002/010551, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
12. U.S. Provisional Patent Application Serial No. 60/362,969, filed March 6, 2002
Title: Methods of Regulation of Metastatic Phenotypes
Inventors: Charles H. Graham, Lynne-Marie Postovit, Michael A. Adams, Jeremy P.W. Heaton
13. U.S. Provisional Patent Application Serial No. 60/362,620, filed March 7, 2002
Title: Methods of Regulation of Metastatic Phenotypes
Inventors: Charles H. Graham, Lynne-Marie Postovit, Michael A. Adams, Jeremy P.W. Heaton
14. U.S. Patent Application Serial No. 10/384,499, filed March 6, 2003
Title: Formulations and Methods of Using Nitric Oxide Mimetic Against a Malignant Cell Phenotype
Inventors: Charles H. Graham, Lynne-Marie Postovit, Michael A. Adams, Jeremy P.W. Heaton
15. International Patent Application Serial No. PCT/CA03/00313, filed March 6, 2003
Title: Formulations and Methods of Using Nitric Oxide Mimetics in Cancer Treatment
Inventors: Charles H. Graham, Lynne-Marie Postovit, Michael A. Adams, Jeremy P.W. Heaton

16. European Patent Application Serial No. 03 706 181.9, filed March 6, 2003
Title: Formulations and Methods of Using Nitric Oxide Mimetics in Cancer Treatment
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
17. Canadian Patent Application Serial No. 2,478,145, filed March 6, 2003
Title: Formulations and Methods of Using Nitric Oxide Mimetics in Cancer Treatment
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
18. Japanese Patent Application Serial No. 2003-572598, filed March 6, 2003
Title: Formulations and Methods of Using Nitric Oxide Mimetics in Cancer Treatment
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
19. Hong Kong Patent No. 1052468, issued November 3, 2004
Hong Kong Patent Application Serial No. 03 104 814.3, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
20. Great Britain Patent No. 1 278 547, issued November 3, 2004
European Patent Application Serial No. 01 923 448.3, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
21. French Patent No. 1 278 547, issued November 3, 2004
European Patent Application Serial No. 01 923 448.3, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
22. Spanish Patent No. 1 278 547, issued November 3, 2004
European Patent Application Serial No. 01 923 448.3, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
23. German Patent No. 60 106 905.6, issued November 3, 2004
European Patent Application Serial No. 01 923 448.3, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit

24. Italian Patent No. 47750BE/2005, issued November 3, 2004
European Patent Application Serial No. 01 923 448.3, filed April 26, 2001
Title: Formulations and Methods of Using Nitric Oxide Mimetics Against a Malignant Cell Phenotype
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit
25. European Patent Application Serial No. 04 105 045.1, filed April 26, 2001
Title: Use of Nitric Oxide Mimetics in Cancer Treatment
Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham, Lynne-Marie Postovit